Chemokine Therapeutics (fka CHKT)

[roelien]

CHKT CEO, Mr Walter Korz is also on the board of directors for Wex Pharmaceuticals and the major shareholder there is Pharmagesic:

Pharmagesic Announces Take Up of Additional Shares of WEX Pharmaceuticals Inc.

02/28/2011

Montreal, Canada (February 28, 2011) – Pharmagesic (Holdings) Inc. (“Pharmagesic”) announced today that pursuant to the offer by its wholly-owned subsidiary, 7735308 Canada Limited (the “Offeror” and, together with Pharmagesic, the “Offering Parties”) to acquire all of the outstanding restricted voting shares (the “WEX Shares”) of WEX Pharmaceuticals Inc. (“WEX”) not already owned by Pharmagesic for C$0.14 cash per WEX Share (the “Offer”) it has taken up an additional 54,590 WEX Shares, which, when added to the WEX Shares previously held, amount to a total of 398,496,186 WEX Shares, representing over 90% of the WEX Shares outstanding. It is the current intention of the Offering Parties to enter into a subsequent acquisition transaction to acquire all of the remaining WEX Shares that are not acquired pursuant to the Offer, which is open until 5:00 p.m. (Vancouver time) on March 10, 2011.

WEX shareholders who have already deposited their WEX Shares to the Offer do not need to take any further action to accept the Offer. Shareholders who have not yet deposited their WEX Shares in acceptance of the Offer may tender their WEX Shares to the Offer at any time prior to 5:00 p.m. (Vancouver time) on March 10, 2011.

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. WEX’s principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market.

About Pharmagesic (Holdings) Inc.

Pharmagesic (Holdings) Inc. is an indirect wholly owned subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”). CKLS is a company listed on The Stock Exchange of Hong Kong Limited (stock code: 0775). Bearing the mission of improving the quality of life, CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing and selling of environmental and human health products, and water business as well as investment in various financial and investment products. Products developed by CKLS are categorized into the areas of human health and environmental sustainability. CKLS is a member of the Cheung Kong Group. For additional information, please visit www.ck-lifesciences.com.